For protection against cancers, both boys and girls benefit from getting HPV vaccine

December 12, 2011 By Neville Golden and Sophia Yen

On Oct. 25, the U.S. Centers for Disease Control and Prevention recommended that all adolescent boys be immunized against the human papilloma virus, which causes several types of cancer in both sexes. We strongly support this landmark decision, which builds on the CDC’s 2006 recommendation to immunize all girls against HPV.

The vaccines, which protect against either two or four HPV strains, could prevent about 60 percent of mouth and throat cancers, 76 percent of cervical , 87 percent of anal cancer, 31 percent of penile cancer and 44 to 56 percent of vulvar and vaginal cancers. Yet some parents are skeptical of vaccination’s value in cancer prevention or reluctant to immunize their sons and daughters against a sexually transmitted disease.

HPV is the No. 1 STD in the . About 6 million Americans are infected each year. Up to 80 percent of adults are infected with this virus during their lifetimes, with half becoming infected within four years of sexual debut. If you have two sexual partners in your lifetime, you have a 70 percent chance of being infected with one of the four common strains covered by the HPV vaccines.

Fortunately, most people’s bodies get rid of HPV infection spontaneously. However, the oncogenic types of HPV, those that cause cancer, are more likely to persist.

To offer the best protection against cancer, the and medical community recommend that the HPV be given at age 11 to 12, before the onset of sexual activity. According to the 2009 national Youth Risk Behavior Survey, more than one out of every 20 high school students reported they had sex before the age of 13, and 32 percent of high school ninth-graders reported they had had sexual intercourse.

The HPV vaccine is a safe and extremely effective vaccine against certain types of HPV, especially the types most likely to cause cancer. More than 35 million doses of the vaccine have been given in the United States. The only major confirmed side effect after continuous surveillance is pain and some risk of fainting within 15-30 minutes after injection.

Two vaccines are available — the quadrivalent one protects against four types of HPV virus (6,11, 16 and 18) and the other protects against two types (16 and 18). Both protect against types 16 and 18, the cancer-causing types of the virus. The quadrivalent vaccine is the only vaccine currently licensed for use in the United States for boys, but either vaccine can be used in girls. There are approximately 160 types of HPV virus.

As adolescent medicine specialists, we want parents who are struggling with the decision to vaccinate their sons and daughters to understand that the vaccine is very low-risk and the protection it confers against several life-threatening cancers is substantial. Parents who are reluctant to think about their children’s future sexual behavior should consider that even young people who are sexually abstinent until marriage are still vulnerable to infection after marriage from a spouse who had been previously infected. In addition, as adolescent medicine physicians, we often see young patients who have become sexually active without their parents’ knowledge.

The HPV vaccine is the first vaccine that has the potential to prevent more than one type of cancer. We strongly support protecting both boys and girls against these cancers by immunizing them before they become sexually active.

Explore further: US patent awarded for Rochester's pioneering HPV vaccine work

Related Stories

US patent awarded for Rochester's pioneering HPV vaccine work

November 22, 2011
The University of Rochester has been awarded a U.S. patent for research essential to both human papillomavirus vaccines on the market.

Lack of clarity about HPV vaccine and the need for cervical cancer screening

July 7, 2011
The research will be presented today at the Annual Scientific Meeting of the Society of Academic Primary Care, hosted this year by the Academic Unit of Primary Health Care, University of Bristol.

Cervical vaccine also protects against anal cancer risk

August 23, 2011
A vaccine routinely used to shield against cervical cancer caused by the human papillomavirus also reduces women's risk of anal cancer, a study published by the journal The Lancet Oncology on Tuesday says.

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Sepp
1 / 5 (1) Dec 12, 2011
Disgusting commercial promotion of vaccines - no mention of serious side effects.

Hundreds of girls who received the vaccines have had serious neurological problems and scores died shortly after being vaccinated.

There is NO justification for such a recommendation. Safety is bad and efficacy of the vaccine in *actually* preventing any cancers has not been proven. What has been observed are antibodies against an essentially benign virus. Where is the cancer connection?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.